Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 2.751
Filtrer
1.
Bull Exp Biol Med ; 177(1): 79-83, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38960955

RÉSUMÉ

A new Mycoplasma hominis phenotype forming mini-colonies (MC) on agar and distinct from the phenotype forming typical colonies (TC) not only in size, but also in morphology, growth rate, and resistance to adverse factors, has been previously identified. In this study, the phenotype of colonies was determined and a comparative analysis of the amino acid sequence of the main variable antigen Vaa of the laboratory strain N-34 and seven clinical isolates of M. hominis was performed. It is demonstrated that the amino acid sequence of Vaa in clinical isolates forming TC (similar to the laboratory strain N-34) is entirely analogous to that of laboratory strain. Clinical isolates forming MC carry amino acid substitutions in the variable C-terminal region of Vaa, which can contribute to adhesion to eukaryotic cells and immune evasion. The connection between colony phenotype and amino acid sequence of Vaa is established.


Sujet(s)
Séquence d'acides aminés , Infections à Mycoplasma , Mycoplasma hominis , Phénotype , Mycoplasma hominis/génétique , Mycoplasma hominis/immunologie , Humains , Infections à Mycoplasma/microbiologie , Infections à Mycoplasma/immunologie , Antigènes bactériens/génétique , Antigènes bactériens/immunologie , Antigènes bactériens/composition chimique , Substitution d'acide aminé
2.
Methods Mol Biol ; 2821: 111-127, 2024.
Article de Anglais | MEDLINE | ID: mdl-38997484

RÉSUMÉ

Immune stimulants (adjuvants) enhance immune system recognition to provide an effective and individualized immune response when delivered with an antigen. Synthetic cyclic deca-peptides, co-administered with a toll-like receptor targeting lipopeptide, have shown self-adjuvant properties, dramatically boosting the immune response in a murine model as a subunit peptide-based vaccine containing group A Streptococcus peptide antigens.Here, we designed a novel peptide and lipid adjuvant system for the delivery of group A Streptococcus peptide antigen and a T helper peptide epitope. Following linear peptide synthesis on 2-chlorotrityl chloride resin, the linear peptide was cleaved and head-to-tail cyclized in solution. The selective arrangement of amino acids in the deca-peptide allowed for selective conjugation of lipids and/or peptide antigens following cyclisation. Using both solution-phase peptide chemistry and copper-catalyzed azide-alkyne cycloaddition reaction were covalently (and selectively) ligated lipid and/or peptide antigens onto the cyclic deca-peptide core. Subcutaneous administration of the vaccine design to mice resulted in the generation of a large number of serum immunoglobulin (Ig) G antibodies.


Sujet(s)
Adjuvants immunologiques , Immunisation , Peptides cycliques , Vaccins conjugués , Animaux , Souris , Peptides cycliques/immunologie , Peptides cycliques/composition chimique , Vaccins conjugués/immunologie , Vaccins conjugués/composition chimique , Vaccins conjugués/administration et posologie , Immunisation/méthodes , Adjuvants immunologiques/composition chimique , Adjuvants immunologiques/administration et posologie , Injections sous-cutanées , Vaccins sous-unitaires/immunologie , Vaccins sous-unitaires/administration et posologie , Vaccins sous-unitaires/composition chimique , Streptococcus pyogenes/immunologie , Immunoglobuline G/immunologie , Immunoglobuline G/sang , Antigènes bactériens/immunologie , Antigènes bactériens/composition chimique ,
3.
ACS Appl Bio Mater ; 7(6): 3877-3889, 2024 Jun 17.
Article de Anglais | MEDLINE | ID: mdl-38832760

RÉSUMÉ

Adjuvants and immunomodulators that effectively drive a Th17-skewed immune response are not part of the standard vaccine toolkit. Vaccine adjuvants and delivery technologies that can induce Th17 or Th1/17 immunity and protection against bacterial pathogens, such as tuberculosis (TB), are urgently needed. Th17-polarized immune response can be induced using agonists that bind and activate C-type lectin receptors (CLRs) such as macrophage inducible C-type lectin (Mincle). A simple but effective strategy was developed for codelivering Mincle agonists with the recombinant Mycobacterium tuberculosis fusion antigen, M72, using tunable silica nanoparticles (SNP). Anionic bare SNP, hydrophobic phenyl-functionalized SNP (P-SNP), and cationic amine-functionalized SNP (A-SNP) of different sizes were coated with three synthetic Mincle agonists, UM-1024, UM-1052, and UM-1098, and evaluated for adjuvant activity in vitro and in vivo. The antigen and adjuvant were coadsorbed onto SNP via electrostatic and hydrophobic interactions, facilitating multivalent display and delivery to antigen presenting cells. The cationic A-SNP showed the highest coloading efficiency for the antigen and adjuvant. In addition, the UM-1098-adsorbed A-SNP formulation demonstrated slow-release kinetics in vitro, excellent stability over 12 months of storage, and strong IL-6 induction from human peripheral blood mononuclear cells. Co-adsorption of UM-1098 and M72 on A-SNP significantly improved antigen-specific humoral and Th17-polarized immune responses in vivo in BALB/c mice relative to the controls. Taken together, A-SNP is a promising platform for codelivery and proper presentation of adjuvants and antigens and provides the basis for their further development as a vaccine delivery platform for immunization against TB or other diseases for which Th17 immunity contributes to protection.


Sujet(s)
Antigènes bactériens , Lectines de type C , Nanoparticules , Silice , Cellules Th17 , Lectines de type C/métabolisme , Lectines de type C/immunologie , Lectines de type C/agonistes , Nanoparticules/composition chimique , Cellules Th17/immunologie , Animaux , Silice/composition chimique , Souris , Antigènes bactériens/immunologie , Antigènes bactériens/administration et posologie , Antigènes bactériens/composition chimique , Mycobacterium tuberculosis/immunologie , Adjuvants immunologiques/composition chimique , Adjuvants immunologiques/pharmacologie , Adjuvants immunologiques/administration et posologie , Matériaux biocompatibles/composition chimique , Matériaux biocompatibles/pharmacologie , Taille de particule , Test de matériaux , Humains , Femelle , Protéines membranaires/immunologie , Protéines membranaires/agonistes
4.
Pathog Dis ; 822024 Feb 07.
Article de Anglais | MEDLINE | ID: mdl-38889932

RÉSUMÉ

Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial infection worldwide, potentially leading to severe pathologies including pelvic inflammatory disease, ectopic pregnancy, and tubal infertility if left untreated. Current strategies, including screening and antibiotics, have limited effectiveness due to high rates of asymptomatic cases and logistical challenges. A multiepitope prophylactic vaccine could afford long-term protection against infection. Immunoinformatic analyses were employed to design a multiepitope Chlamydia vaccine antigen. B- and T-cell epitopes from five highly conserved and immunogenic Ct antigens were predicted and selected for the vaccine design. The final construct, adjuvanted with cholera toxin A1 subunit (CTA1), was further screened for immunogenicity. CTA1-MECA (multiepitope Chlamydia trachomatis antigen) was identified as antigenic and nonallergenic. A tertiary structure was predicted, refined, and validated as a good quality model. Molecular docking exhibited strong interactions between the vaccine and toll-like receptor 4 (TLR4). Additionally, immune responses consistent with protection including IFN-γ, IgG + IgM antibodies, and T- and B-cell responses were predicted following vaccination in an immune simulation. Expression of the construct in an Escherichia coli expression vector proved efficient. To further validate the vaccine efficacy, we assessed its immunogenicity in mice. Immunization with CTA1-MECA elicited high levels of Chlamydia-specific antibodies in mucosal and systemic compartments.


Sujet(s)
Anticorps antibactériens , Vaccins antibactériens , Infections à Chlamydia , Chlamydia trachomatis , Déterminants antigéniques des lymphocytes B , Déterminants antigéniques des lymphocytes T , Simulation de docking moléculaire , Vaccins antibactériens/immunologie , Vaccins antibactériens/génétique , Infections à Chlamydia/prévention et contrôle , Infections à Chlamydia/immunologie , Animaux , Chlamydia trachomatis/immunologie , Déterminants antigéniques des lymphocytes T/immunologie , Souris , Anticorps antibactériens/immunologie , Anticorps antibactériens/sang , Déterminants antigéniques des lymphocytes B/immunologie , Déterminants antigéniques des lymphocytes B/génétique , Femelle , Antigènes bactériens/immunologie , Antigènes bactériens/composition chimique , Antigènes bactériens/génétique , Simulation numérique , Épitopes/immunologie , Humains , Récepteur de type Toll-4/immunologie , Récepteur de type Toll-4/métabolisme , Toxine cholérique/immunologie , Toxine cholérique/génétique , Modèles animaux de maladie humaine
5.
Helicobacter ; 29(3): e13104, 2024.
Article de Anglais | MEDLINE | ID: mdl-38923222

RÉSUMÉ

Helicobacter pylori (H. pylori) strain is the most genetically diverse pathogenic bacterium and now alarming serious human health concern ranging from chronic gastritis to gastric cancer and human death all over the world. Currently, the majority of commercially available diagnostic assays for H. pylori is a challenging task due to the heterogeneity of virulence factors in various geographical regions. In this concern, designing of universal multi-epitope immunogenic biomarker targeted for all H. pylori strains would be crucial to successfully immunodiagnosis assay and vaccine development for H. pylori infection. Hence, the present study aimed to explore the potential immunogenic epitopes of PSA D15 and Cag11 proteins of H. pylori, using immunoinformatics web tools in order to design novel immune-reactive multi-epitope antigens for enhanced immunodiagnosis in humans. Through an in silico immunoinformatics approach, high-ranked B-cell, MHC-I, and MHC-II epitopes of PSA D15 and Cag11 proteins were predicted, screened, and selected. Subsequently, a novel multi-epitope PSA D15 and Cag11 antigens were designed by fused the high-ranked B-cell, MHC-I, and MHC-II epitopes and 50S ribosomal protein L7/L12 adjuvant using linkers. The antigenicity, solubility, physicochemical properties, secondary and tertiary structures, 3D model refinement, and validations were carried. Furthermore, the designed multi-epitope antigens were subjected to codon adaptation and in silico cloning, immune response simulation, and molecular docking with receptor molecules. A novel, stable multi-epitope PSA D15 and Cag11 H. pylori antigens were developed and immune simulation of the designed antigens showed desirable levels of immunological response. Molecular docking of designed antigens with immune receptors (B-cell, MHC-I, MHC-II, and TLR-2/4) revealed robust interactions and stable binding affinity to the receptors. The codon optimized and in silico cloned showed that the designed antigens were successfully expressed (CAI value of 0.95 for PSA D15 and 1.0 for Cag11) after inserted into pET-32ba (+) plasmid of the E. coli K12 strain. In conclusion, this study revealed that the designed multi-epitope antigens have a huge immunological potential candidate biomarker and useful in developing immunodiagnostic assays and vaccines for H. pylori infection.


Sujet(s)
Antigènes bactériens , Biologie informatique , Helicobacter pylori , Helicobacter pylori/immunologie , Helicobacter pylori/génétique , Antigènes bactériens/immunologie , Antigènes bactériens/génétique , Antigènes bactériens/composition chimique , Humains , Infections à Helicobacter/diagnostic , Infections à Helicobacter/immunologie , Infections à Helicobacter/microbiologie , Protéines bactériennes/immunologie , Protéines bactériennes/génétique , Protéines bactériennes/composition chimique , Épitopes/immunologie , Tests immunologiques/méthodes , Simulation de docking moléculaire , Vaccins antibactériens/immunologie , Vaccins antibactériens/génétique ,
6.
J Biol Chem ; 300(7): 107478, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38879009

RÉSUMÉ

Antigenically sequence variable M proteins of the major bacterial pathogen Streptococcus pyogenes (Strep A) are responsible for recruiting human C4b-binding protein (C4BP) to the bacterial surface, which enables Strep A to evade destruction by the immune system. The most sequence divergent portion of M proteins, the hypervariable region (HVR), is responsible for binding C4BP. Structural evidence points to the conservation of two C4BP-binding sequence patterns (M2 and M22) in the HVR of numerous M proteins, with this conservation applicable to vaccine immunogen design. These two patterns, however, only partially explain C4BP binding by Strep A. Here, we identified several M proteins that lack these patterns but still bind C4BP and determined the structures of two, M68 and M87 HVRs, in complex with a C4BP fragment. Mutagenesis of these M proteins led to the identification of amino acids that are crucial for C4BP binding, enabling formulation of new C4BP-binding patterns. Mutagenesis was also carried out on M2 and M22 proteins to refine or generate experimentally grounded C4BP-binding patterns. The M22 pattern was the most prevalent among M proteins, followed by the M87 and M2 patterns, while the M68 pattern was rare. These patterns, except for M68, were also evident in numerous M-like Enn proteins. Binding of C4BP via these patterns to Enn proteins was verified. We conclude that C4BP-binding patterns occur frequently in Strep A strains of differing M types, being present in their M or Enn proteins, or frequently both, providing further impetus for their use as vaccine immunogens.


Sujet(s)
Antigènes bactériens , Protéine de liaison à C4b , Streptococcus pyogenes , Streptococcus pyogenes/métabolisme , Streptococcus pyogenes/génétique , Streptococcus pyogenes/composition chimique , Protéine de liaison à C4b/métabolisme , Antigènes bactériens/métabolisme , Antigènes bactériens/composition chimique , Antigènes bactériens/génétique , Humains , Protéines de la membrane externe bactérienne/métabolisme , Protéines de la membrane externe bactérienne/composition chimique , Protéines de la membrane externe bactérienne/génétique , Protéines de transport/métabolisme , Protéines de transport/génétique , Protéines de transport/composition chimique , Liaison aux protéines , Séquence d'acides aminés , Protéines bactériennes/métabolisme , Protéines bactériennes/composition chimique , Protéines bactériennes/génétique
7.
Anal Methods ; 16(22): 3464-3474, 2024 Jun 06.
Article de Anglais | MEDLINE | ID: mdl-38804556

RÉSUMÉ

The unambiguous identification of protein species requires high sequence coverage. In this study, we successfully improved the sequence coverage of early secretory 10 kDa cell filtrate protein (CFP-10) and 6 kDa early secretory antigenic target (ESAT-6) proteins from the Mycobacterium tuberculosis complex (MTC) in broth culture media with the use of the 4-chloro-α-cyanocinnamic acid (Cl-CCA) matrix. Conventional matrices, α-cyano-hydroxy-cinnamic acid (CHCA) and 2,5-dihydroxybenzoic acid (DHB), were also used for comparison. After nanodiamond (ND) extraction, the sequence coverage of the CFP-10 protein was 87% when CHCA and DHB matrices were used, and the ESAT-6 protein was not detected. On the other hand, the sequence coverage for ND-extracted CFP-10 and ESAT-6 could reach 94% and 100%, respectively, when the Cl-CCA matrix was used and with the removal of interference from bovine serum albumin (BSA) protein and α-crystallin (ACR) protein. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) was also adopted to analyze the protein mass spectra. A total of 6 prominent ion signals were observed, including ESAT-6 protein peaks at mass-to-charge ratios (m/z) of ∼7931, ∼7974, ∼9768, and ∼9813 and CFP-10 protein peaks at m/z of ∼10 100 and ∼10 660. The ESAT-6 ion signals were always detected concurrently with CFP-10 ion signals, but CFP-10 ion signals could be detected alone without the ESAT-6 ion signals. Furthermore, the newly found ESAT-6 peaks were also confirmed using a Mag-Beads-Protein G kit with an ESAT-6 antibody to capture the ESAT-6 protein, which was also consistent with the sequence coverage analysis.


Sujet(s)
Antigènes bactériens , Protéines bactériennes , Mycobacterium tuberculosis , Nanodiamants , Mycobacterium tuberculosis/composition chimique , Protéines bactériennes/composition chimique , Nanodiamants/composition chimique , Antigènes bactériens/composition chimique , Antigènes bactériens/isolement et purification , Spectrométrie de masse MALDI/méthodes
8.
Sci Rep ; 14(1): 10375, 2024 05 06.
Article de Anglais | MEDLINE | ID: mdl-38710737

RÉSUMÉ

Tuberculosis (TB) a disease caused by Mycobacterium tuberculosis (Mtb) poses a significant threat to human life, and current BCG vaccinations only provide sporadic protection, therefore there is a need for developing efficient vaccines. Numerous immunoinformatic methods have been utilized previously, here for the first time a deep learning framework based on Deconvolutional Neural Networks (DCNN) and Bidirectional Long Short-Term Memory (DCNN-BiLSTM) was used to predict Mtb Multiepitope vaccine (MtbMEV) subunits against six Mtb H37Rv proteins. The trained model was used to design MEV within a few minutes against TB better than other machine learning models with 99.5% accuracy. The MEV has good antigenicity, and physiochemical properties, and is thermostable, soluble, and hydrophilic. The vaccine's BLAST search ruled out the possibility of autoimmune reactions. The secondary structure analysis revealed 87% coil, 10% beta, and 2% alpha helix, while the tertiary structure was highly upgraded after refinement. Molecular docking with TLR3 and TLR4 receptors showed good binding, indicating high immune reactions. Immune response simulation confirmed the generation of innate and adaptive responses. In-silico cloning revealed the vaccine is highly expressed in E. coli. The results can be further experimentally verified using various analyses to establish a candidate vaccine for future clinical trials.


Sujet(s)
Mycobacterium tuberculosis , , Vaccins antituberculeux , Vaccins antituberculeux/immunologie , Mycobacterium tuberculosis/immunologie , Humains , Simulation de docking moléculaire , Développement de vaccin/méthodes , Épitopes/immunologie , Tuberculose/prévention et contrôle , Tuberculose/immunologie , Antigènes bactériens/immunologie , Antigènes bactériens/composition chimique
9.
Biochem Biophys Res Commun ; 717: 150040, 2024 Jul 12.
Article de Anglais | MEDLINE | ID: mdl-38718566

RÉSUMÉ

Mtb12, a small protein secreted by Mycobacterium tuberculosis, is known to elicit immune responses in individuals infected with the pathogen. It serves as an antigen recognized by the host's immune system. Due to its immunogenic properties and pivotal role in tuberculosis (TB) pathogenesis, Mtb12 is considered a promising candidate for TB diagnosis and vaccine development. However, the structural and functional properties of Mtb12 are largely unexplored, representing a significant gap in our understanding of M. tuberculosis biology. In this study, we present the first structure of Mtb12, which features a unique tertiary configuration consisting of four beta strands and four alpha helices. Structural analysis reveals that Mtb12 has a surface adorned with a negatively charged pocket adjacent to a central cavity. The features of these structural elements and their potential effects on the function of Mtb12 warrant further exploration. These findings offer valuable insights for vaccine design and the development of diagnostic tools.


Sujet(s)
Antigènes bactériens , Protéines bactériennes , Mycobacterium tuberculosis , Mycobacterium tuberculosis/immunologie , Mycobacterium tuberculosis/métabolisme , Antigènes bactériens/composition chimique , Antigènes bactériens/immunologie , Protéines bactériennes/composition chimique , Protéines bactériennes/immunologie , Protéines bactériennes/métabolisme , Modèles moléculaires , Masse moléculaire , Séquence d'acides aminés , Conformation des protéines , Humains
10.
ACS Biomater Sci Eng ; 10(5): 3387-3400, 2024 05 13.
Article de Anglais | MEDLINE | ID: mdl-38656158

RÉSUMÉ

Given the worldwide problem posed by enteric pathogens, the discovery of safe and efficient intestinal adjuvants combined with novel antigen delivery techniques is essential to the design of mucosal vaccines. In this work, we designed poly (lactic-co-glycolic acid) (PLGA)-based nanoparticles (NPs) to codeliver all-trans retinoic acid (atRA), novel antigens, and CpG. To address the insolubility of the intestinal adjuvant atRA, we utilized PLGA to encapsulate atRA and form a "nanocapsid" with polydopamine. By leveraging polydopamine, we adsorbed the water-soluble antigens and the TLR9 agonist CpG onto the NPs' surface, resulting in the pathogen-mimicking PLPCa NPs. In this study, the novel fusion protein (HBf), consisting of the Mycobacterium avium subspecies paratuberculosis antigens HBHA, Ag85B, and Bfra, was coloaded onto the NPs. In vitro, PLPCa NPs were shown to promote the activation and maturation of bone marrow-derived dendritic cells. Additionally, we found that PLPCa NPs created an immune-rich microenvironment at the injection site following intramuscular administration. From the results, the PLPCa NPs induced strong IgA levels in the gut in addition to enhancing powerful systemic immune responses. Consequently, significant declines in the bacterial burden and inflammatory score were noted in PLPCa NPs-treated mice. In summary, PLPCa can serve as a novel and safe vaccine delivery platform against gut pathogens, such as paratuberculosis, capable of activating both systemic and intestinal immunity.


Sujet(s)
Nanoparticules , Paratuberculose , Animaux , Nanoparticules/composition chimique , Paratuberculose/immunologie , Paratuberculose/prévention et contrôle , Souris , Trétinoïne/composition chimique , Trétinoïne/pharmacologie , Mycobacterium avium ssp. paratuberculosis/immunologie , Copolymère d'acide poly(lactique-co-glycolique)/composition chimique , Antigènes bactériens/immunologie , Antigènes bactériens/composition chimique , Cellules dendritiques/immunologie , Cellules dendritiques/effets des médicaments et des substances chimiques , Intestins/immunologie , Intestins/microbiologie , Souris de lignée C57BL , Femelle , Adjuvants immunologiques/pharmacologie , Adjuvants immunologiques/composition chimique , Adjuvants immunologiques/administration et posologie , Vaccins antibactériens/immunologie , Souris de lignée BALB C
11.
Biomolecules ; 14(4)2024 Apr 11.
Article de Anglais | MEDLINE | ID: mdl-38672487

RÉSUMÉ

Tuberculosis (TB) is the leading global cause of death f rom an infectious bacterial agent. Therefore, limiting its epidemic spread is a pressing global health priority. The chaperone-like protein HtpG of M. tuberculosis (Mtb) is a large dimeric and multi-domain protein with a key role in Mtb pathogenesis and promising antigenic properties. This dual role, likely associated with the ability of Heat Shock proteins to act both intra- and extra-cellularly, makes HtpG highly exploitable both for drug and vaccine development. This review aims to gather the latest updates in HtpG structure and biological function, with HtpG operating in conjunction with a large number of chaperone molecules of Mtb. Altogether, these molecules help Mtb recovery after exposure to host-like stress by assisting the whole path of protein folding rescue, from the solubilisation of aggregated proteins to their refolding. Also, we highlight the role of structural biology in the development of safer and more effective subunit antigens. The larger availability of structural information on Mtb antigens and a better understanding of the host immune response to TB infection will aid the acceleration of TB vaccine development.


Sujet(s)
Antigènes bactériens , Protéines bactériennes , Mycobacterium tuberculosis , Vaccins antituberculeux , Facteurs de virulence , Mycobacterium tuberculosis/immunologie , Antigènes bactériens/immunologie , Antigènes bactériens/composition chimique , Facteurs de virulence/immunologie , Facteurs de virulence/composition chimique , Humains , Vaccins antituberculeux/immunologie , Protéines bactériennes/immunologie , Protéines bactériennes/composition chimique , Tuberculose/immunologie , Tuberculose/prévention et contrôle , Tuberculose/microbiologie , Animaux , Chaperons moléculaires/immunologie , Chaperons moléculaires/composition chimique , Chaperons moléculaires/métabolisme
12.
J Mol Biol ; 436(8): 168521, 2024 Apr 15.
Article de Anglais | MEDLINE | ID: mdl-38458604

RÉSUMÉ

Dedicated translocase channels are nanomachines that often, but not always, unfold and translocate proteins through narrow pores across the membrane. Generally, these molecular machines utilize external sources of free energy to drive these reactions, since folded proteins are thermodynamically stable, and once unfolded they contain immense diffusive configurational entropy. To catalyze unfolding and translocate the unfolded state at appreciable timescales, translocase channels often utilize analogous peptide-clamp active sites. Here we describe how anthrax toxin has been used as a biophysical model system to study protein translocation. The tripartite bacterial toxin is composed of an oligomeric translocase channel, protective antigen (PA), and two enzymes, edema factor (EF) and lethal factor (LF), which are translocated by PA into mammalian host cells. Unfolding and translocation are powered by the endosomal proton gradient and are catalyzed by three peptide-clamp sites in the PA channel: the α clamp, the ϕ clamp, and the charge clamp. These clamp sites interact nonspecifically with the chemically complex translocating chain, serve to minimize unfolded state configurational entropy, and work cooperatively to promote translocation. Two models of proton gradient driven translocation have been proposed: (i) an extended-chain Brownian ratchet mechanism and (ii) a proton-driven helix-compression mechanism. These models are not mutually exclusive; instead the extended-chain Brownian ratchet likely operates on ß-sheet sequences and the helix-compression mechanism likely operates on α-helical sequences. Finally, we compare and contrast anthrax toxin with other related and unrelated translocase channels.


Sujet(s)
Bacillus anthracis , Toxines bactériennes , Animaux , Protons , Antigènes bactériens/composition chimique , Toxines bactériennes/métabolisme , Transport des protéines , Peptides/métabolisme , Bacillus anthracis/composition chimique , Mammifères/métabolisme
13.
Carbohydr Polym ; 330: 121731, 2024 Apr 15.
Article de Anglais | MEDLINE | ID: mdl-38368077

RÉSUMÉ

Enterococcus faecium, a gram-positive opportunistic pathogen, has become a major concern for nosocomial infections due to its resistance to several antibiotics, including vancomycin. Finding novel alternatives for treatment prevention, such as vaccines, is therefore crucial. In this study, we used various techniques to discover a novel capsular polysaccharide. Firstly, we identified an encapsulated E. faecium strain by evaluating the opsonophagocytic activity of fifteen strains with antibodies targeting the well-known lipoteichoic acid antigen. This activity was attributed to an unknown polysaccharide. We then prepared a crude cell wall glycopolymer and fractionated it, guided by immunodot-blot analysis. The most immunoreactive fractions were used for opsonophagocytic inhibition assays. The fraction containing the inhibitory polysaccharide underwent structural characterization using NMR and chemical analyses. The elucidated structure presents a branched repeating unit, with the linear part being: →)-ß-d-Gal-(1 â†’ 4)-ß-d-Glc-(1 â†’ 4)-ß-d-Gal-(1 â†’ 4)-ß-d-GlcNAc-(1→, further decorated with a terminal α-d-Glc and a d-phosphoglycerol moiety, attached to O-2 and O-3 of the 4-linked Gal unit, respectively. This polysaccharide was conjugated to BSA and the synthetic glycoprotein used to immunize mice. The resulting sera exhibited good opsonic activity, suggesting its potential as a vaccine antigen. In conclusion, our effector-function-based approach successfully identified an immunogenic capsular polysaccharide with promising applications in immunotherapy.


Sujet(s)
Antigènes bactériens , Enterococcus faecium , Souris , Animaux , Antigènes bactériens/composition chimique , Enterococcus faecium/composition chimique , Opsonines , Polyosides , Anticorps antibactériens , Développement de vaccin
14.
Biomater Sci ; 11(22): 7229-7246, 2023 Nov 07.
Article de Anglais | MEDLINE | ID: mdl-37791425

RÉSUMÉ

Fimbriae are long filamentous polymeric protein structures located upon the surface of bacteria. Often implicated in pathogenicity, the biosynthesis and function of fimbriae has been a productive topic of study for many decades. Evolutionary pressures have ensured that fimbriae possess unique structural and mechanical properties which are advantageous to bacteria. These properties are also difficult to engineer with well-known synthetic and natural fibres, and this has raised an intriguing question: can we exploit the unique properties of bacterial fimbriae in useful ways? Initial work has set out to explore this question by using Capsular antigen fragment 1 (Caf1), a fimbriae expressed naturally by Yersina pestis. These fibres have evolved to 'shield' the bacterium from the immune system of an infected host, and thus are rather bioinert in nature. Caf1 is, however, very amenable to structural mutagenesis which allows the incorporation of useful bioactive functions and the modulation of the fibre's mechanical properties. Its high-yielding recombinant synthesis also ensures plentiful quantities of polymer are available to drive development. These advantageous features make Caf1 an archetype for the development of new polymers and materials based upon bacterial fimbriae. Here, we cover recent advances in this new field, and look to future possibilities of this promising biopolymer.


Sujet(s)
Antigènes bactériens , Yersinia pestis , Antigènes bactériens/composition chimique , Antigènes bactériens/métabolisme , Protéines bactériennes/composition chimique , Fimbriae bactériens/métabolisme , Polymères/composition chimique , Sciences des matériaux , Yersinia pestis/composition chimique , Yersinia pestis/métabolisme
15.
SAR QSAR Environ Res ; 34(6): 501-521, 2023.
Article de Anglais | MEDLINE | ID: mdl-37462112

RÉSUMÉ

Gastric cancer (GC) is the fifth most prevalent form of cancer worldwide. CagA - positive Helicobacter pylori infects more than 60% of the human population. Moreover, chronic infection of CagA-positive H. pylori can directly affect GC incidence. In the current study, we have repurposed FDA-approved antibiotics that are viable alternatives to current regimens and can potentially be used as combination therapy against the CagA of H. pylori. The 100 FDA-approved gram negative antibiotics were screened against CagA protein using the AutoDock 4.2 tool. Further, top nine compounds were selected based on higher binding affinity with CagA. The trajectory analysis of MD simulations reflected that binding of these drugs with CagA stabilizes the system. Nonetheless, atomic density map and principal component analysis also support the notion of stable binding of antibiotics to the protein. The residues ASP96, GLN100, PRO184, and THR185 of compound cefpiramide, doxycycline, delafloxacin, metacycline, oxytetracycline, and ertapenem were involved in the binding with CagA protein. These residues are crucial for the CagA that aids in entry or pathogenesis of the bacterium. The screened FDA-approved antibiotics have a potential druggability to inhibit CagA and reduce the progression of H. pylori borne diseases.


Sujet(s)
Protéines bactériennes , Tumeurs de l'estomac , Humains , Antibactériens/pharmacologie , Antigènes bactériens/composition chimique , Antigènes bactériens/métabolisme , Protéines bactériennes/composition chimique , Simulation de dynamique moléculaire , Protéines oncogènes/métabolisme , Relation quantitative structure-activité , Tumeurs de l'estomac/traitement médicamenteux , Tumeurs de l'estomac/microbiologie , Tumeurs de l'estomac/anatomopathologie
16.
Chem Biol Drug Des ; 102(4): 669-675, 2023 10.
Article de Anglais | MEDLINE | ID: mdl-37286890

RÉSUMÉ

Detection of anthrax protective antigen is an effective way to diagnose anthracnose, and it plays an important part in the treatment of anthracnose. Affinity peptides, as a miniature biological recognition element, can quickly and effectively detect anthrax protective antigens. Based on computer-aided design technology (CAD), we have herein developed an affinity peptide design strategy for the detection of anthrax protective antigens. Firstly, six high-value mutation sites were determined based on the molecular docking between the template peptide and the receptor, and then the multi-site mutation of amino acids was carried out in order to establish a virtual peptide library. The library was selected by using molecular dynamics simulation and the best designed affinity peptide (code: P24) was found. The theoretical affinity with P24 peptide has increased by 19.8% compared with template peptide. Finally, the affinity with P24 peptide was measured by SPR technology to reach the nanomole level, which verified the effectiveness of the design strategy. The newly designed affinity peptide is expected to be used in the diagnosis of anthracnose.


Sujet(s)
Maladie du charbon , Humains , Simulation de docking moléculaire , Antigènes bactériens/génétique , Antigènes bactériens/composition chimique , Peptides
17.
J Biol Chem ; 299(8): 104980, 2023 08.
Article de Anglais | MEDLINE | ID: mdl-37390991

RÉSUMÉ

Coiled coil-forming M proteins of the widespread and potentially deadly bacterial pathogen Streptococcus pyogenes (strep A) are immunodominant targets of opsonizing antibodies. However, antigenic sequence variability of M proteins into >220 M types, as defined by their hypervariable regions (HVRs), is considered to limit M proteins as vaccine immunogens because of type specificity in the antibody response. Surprisingly, a multi-HVR immunogen in clinical vaccine trials was shown to elicit M-type crossreactivity. The basis for this crossreactivity is unknown but may be due in part to antibody recognition of a 3D pattern conserved in many M protein HVRs that confers binding to human complement C4b-binding protein (C4BP). To test this hypothesis, we investigated whether a single M protein immunogen carrying the 3D pattern would elicit crossreactivity against other M types carrying the 3D pattern. We found that a 34-amino acid sequence of S. pyogenes M2 protein bearing the 3D pattern retained full C4BP-binding capacity when fused to a coiled coil-stabilizing sequence from the protein GCN4. We show that this immunogen, called M2G, elicited cross-reactive antibodies against a number of M types that carry the 3D pattern but not against those that lack the 3D pattern. We further show that the M2G antiserum-recognized M proteins displayed natively on the strep A surface and promoted the opsonophagocytic killing of strep A strains expressing these M proteins. As C4BP binding is a conserved virulence trait of strep A, we propose that targeting the 3D pattern may prove advantageous in vaccine design.


Sujet(s)
Antigènes bactériens , Protéines de la membrane externe bactérienne , Protéines de transport , Streptococcus pyogenes , Humains , Antigènes bactériens/composition chimique , Antigènes bactériens/immunologie , Protéines de la membrane externe bactérienne/composition chimique , Protéines de la membrane externe bactérienne/immunologie , Protéines de transport/composition chimique , Protéines de transport/immunologie , Liaison aux protéines , Streptococcus pyogenes/immunologie , Réactions croisées
18.
Vet Res ; 54(1): 31, 2023 Apr 04.
Article de Anglais | MEDLINE | ID: mdl-37016427

RÉSUMÉ

The available differentiating tests for Chlamydia are based on detection of genetic material and only give information about the actual infection status, but reveal nothing of past infections. As the use of serological methods increases the window of detection, the goal of this study was to investigate if it is possible to develop a differentiating serological test for antibodies against Chlamydia species in chicken sera. Focus was on C. psittaci, C. gallinacea, and two closely related species, i.e. C. abortus and C. avium. To enable differentiating serology, a bead-based Luminex suspension array was constructed, using peptides as antigens, derived from known immunoreactive Chlamydia proteins. For the majority of these peptides, species-specific seroreactivity in mammalian sera has been reported in literature. The suspension array correctly identified antibodies against various Chlamydia species in sera from experimentally infected mice, and was also able to differentiate between antibodies against C. psittaci and C. gallinacea in sera from experimentally infected chickens. In field sera, signals were difficult to interpret as insufficient sera from experimentally infected chickens were available for evaluating the seroreactivity of all peptides. Nevertheless, results of the suspension array with field sera are supported by published data on the occurrence of C. gallinacea in Dutch layers, thereby demonstrating the proof of concept of multiplex serology for Chlamydial species in poultry.


Sujet(s)
Anticorps antibactériens , Antigènes bactériens , Techniques bactériologiques , Infections à Chlamydia , Peptides , Animaux , Souris , Anticorps antibactériens/sang , Antigènes bactériens/composition chimique , Antigènes bactériens/métabolisme , Poulets , Chlamydia , Infections à Chlamydia/diagnostic , Infections à Chlamydia/médecine vétérinaire , Peptides/composition chimique , Peptides/métabolisme , Techniques bactériologiques/méthodes , Techniques bactériologiques/médecine vétérinaire
19.
Biomed Pharmacother ; 155: 113557, 2022 Nov.
Article de Anglais | MEDLINE | ID: mdl-36115112

RÉSUMÉ

Vaccines against Brucella abortus, B. melitensis and B. suis have been based on weakened or killed bacteria, however there is no recombinant vaccine for disease prevention or therapy. This study attempted to predict IFN-γ epitopes, T cell cytotoxicity, and T lymphocytes in order to produce a multiepitope vaccine based on BtpA, Omp16, Omp28, virB10, Omp25, and Omp31 antigens against B. melitensis, B. abortus, and B. suis. AAY, GPGPG, and EAAAK peptides were used as epitope linkers, while the PADRE sequence was used as a Toll-like receptor 2 (TLR2) and TLR4 agonist. The final construct included 389 amino acids, and was a soluble protein with a molecular weight of 41.3 kDa, and nonallergenic and antigenic properties. Based on molecular docking studies, molecular dynamics simulations such as Gyration, RMSF, and RMSD, as well as tertiary structure validation methods, the modeled protein had a stable structure capable of interacting with TLR2/4. As a result, this novel vaccine may stimulate immune responses in B and T cells, and could prevent infection by B. suis, B. abortus, and B. melitensis.


Sujet(s)
Brucella melitensis , Brucellose , Humains , Récepteur de type Toll-2 , Cartographie épitopique , Déterminants antigéniques des lymphocytes T , Brucellose/prévention et contrôle , Brucellose/microbiologie , Récepteur de type Toll-4 , Simulation de docking moléculaire , Antigènes bactériens/composition chimique , Acides aminés
20.
J Mol Biol ; 434(12): 167623, 2022 06 30.
Article de Anglais | MEDLINE | ID: mdl-35533763

RÉSUMÉ

Pathogenic Staphylococcus aureus actively acquires iron from human hemoglobin (Hb) using the IsdH surface receptor. Heme extraction is mediated by a tri-domain unit within the receptor that contains its second (N2) and third (N3) NEAT domains joined by a helical linker domain. Extraction occurs within a dynamic complex, in which receptors engage each globin chain; the N2 domain tightly binds to Hb, while substantial inter-domain motions within the receptor enable its N3 domain to transiently distort the globin's heme pocket. Using molecular simulations coupled with Markov modeling, along with stopped-flow experiments to quantitatively measure heme transfer kinetics, we show that directed inter-domain motions within the receptor play a critical role in the extraction process. The directionality of N3 domain motion and the rate of heme extraction is controlled by amino acids within a short, flexible inter-domain tether that connects the N2 and linker domains. In the wild-type receptor directed motions originating from the tether enable the N3 domain to populate configurations capable of distorting Hb's pocket, whereas mutant receptors containing altered tethers are less able to adopt these conformers and capture heme slowly via indirect processes in which Hb first releases heme into the solvent. Thus, our results show inter-domain motions within the IsdH receptor play a critical role in its ability to extract heme from Hb and highlight the importance of directed motions by the short, unstructured, amino acid sequence connecting the domains in controlling the directionality and magnitude of these functionally important motions.


Sujet(s)
Antigènes bactériens , Hème , Hémoglobines , Récepteurs de surface cellulaire , Infections à staphylocoques , Staphylococcus aureus , Antigènes bactériens/composition chimique , Antigènes bactériens/génétique , Hème/composition chimique , Hémoglobines/composition chimique , Humains , Simulation de dynamique moléculaire , Déplacement , Domaines protéiques , Récepteurs de surface cellulaire/composition chimique , Récepteurs de surface cellulaire/génétique , Infections à staphylocoques/microbiologie , Staphylococcus aureus/pathogénicité
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE